Given the significant TAM of GLP-1 medications, we expect there to be competition, but it could take years for competitors to make any inroads given the time it takes to bring new drugs to market
Chronic Disease Prevalence : Rising global rates of type 2 diabetes and obesity are expanding the patient pool for GLP1 therapies, increasing demand for both glycemic and weight management indications
Oral administration of MK-677 at 4 mg/kg significantly increased GH concentrations with a 1.8-fold increase in peak GH concentration (45.7 ng/mL), whereas administration of distilled water did not increase GH concentrations
Numerous factors influence its level, including kidney function, age, gender, diet, composition of the intestinal microbiota, and liver FMO activity
Developed by Novo Nordisk as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), semaglutide emerged from efforts to create longer-acting diabetes medications with improved glycemic control and potential cardiovascular benefits